

Supplemental table 1

Inhibitor	Company	Article number
A438079 Hydrochloride	MCE	HY-15488A
Secondary antibody (goat anti-rabbit general secondary antibody)	MCE	HY-100714A


Supplemental table 2

a.Sequences of Primers


Target Name	Primer	
P2X7	P2X7-F	AGCTCTGTGCACACCAAGGT
	P2X7-R	GTAGTCGGCCGTGTCTGAAGA
GAPDH	GAPDH-F	AAGATGGTGAAGGTCGGTGT
	GAPDH-R	GCTTCCCATTCTCAGCCTTG
miRNA9	miRNA9-R	GTCGTATCCAGTGCAGGGTCCGAGGTATTTCGCACTGG
	T Primer	ATACGACACTTTC
	miRNA9-F	CGCGCGATAAAGCTAGATAACC
	miRNA9-R	AGTGCAGGGTCCGAGGTATT

b.Amplification and Melt Peak of PCR


GADPH



P2RX7



MiR-9



Supplemental table 3

Antibody	Company	Article number	Dilution ratio
Primary antibody P2RX7(rabbit KD:70-80)	Abcam	ab109054	1:2000
Primary antibody ACTIN(mouse KD:42)	Servicebio	GB12001	1:3000
Secondary antibody (rabbit anti-rabbit general secondary antibody)	Servicebio	GB25301	1:5000
Secondary antibody (mouse anti-rabbit general secondary antibody)	Servicebio	GB23303	1:5000

Supplemental table 4

Antibody	Company	Article number	Dilution ratio
Primary antibody IBA1	abcam	Ab178846	1:400
Secondary antibody (goat anti-rabbit general secondary antibody)	DAKO	K5007	Directly use without dilution

Table I Systolic blood pressure of SHRs and WKY rats(mmHg)

Group (n=5)	SBP in different date of treatment (mean $\pm$ SD)				
	Day 0	Day 3	Day 7	Day 10	Day 14

Sham	167.6 ± 2.88 ^a	168.4 ± 2.41	169.4 ± 3.04 ^b	170.0 ± 4.18	172.4 ± 2.30 ^c
nonsti-Control	167.0 ± 3.39 ^a	167.4 ± 2.30	169.0 ± 2.91	169.4 ± 2.40	171.6 ± 2.07
miR9-inhibitor+EA	166.2 ± 1.30 ^a	164.4 ± 1.67	162.8 ± 0.84	162.2 ± 0.83	161.4 ± 2.07 ^{cd}
P2RX7-inhibitor+EA	166.4 ± 3.36 ^a	165.6 ± 2.88	162.4 ± 3.70 ^b	160.8 ± 2.50	157.8 ± 1.64 ^{cde}
EA	167.0 ± 2.23 ^a	166.2 ± 1.30	163.8 ± 1.48 ^b	161.6 ± 2.64	158.0 ± 1.58 ^{cde}
WKY	110.4 ± 3.20 ^a	111.0 ± 2.00	111.4 ± 3.50	109.4 ± 3.91	108.8 ± 2.58

Table 1 Systolic blood pressure of SHR and WKY rats; ^aP<0.001 all of SHR vs. WKY rats; SBP after 7 days treatment, ^bP<0.05, P2RX7-inhibitor+EA and EA group vs. Sham; SBP after 14 days treatment, ^cP<0.01, All EA groups vs. Sham; ^dP<0.05, P2RX7-inhibitor+EA and EA group vs. miR9-inhibitor+EA; ^eP>0.05, there was no significance between P2RX7-inhibitor+EA and EA group.